I. de Torres, J. Pallarés, J. Castellví, J. de la Torre, A. Mas, A. Colomer*, M. Guix*
Anatomía Patológica Hospital Vall d’Hebron. *BIOPAT. Grup Assistència.
Manuel Guix1,2, Anna Colomer1, Nadina Erill1, M. Assumpció Cañadas2, Ruth Román1, Xavier Puig1,2, Carlos Cordón-Cardó3.
1BIOPAT, Grup Assistència, Barcelona; 2HISTOPAT Laboratoris, Barcelona; 3Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York.
Multiple studies using primary tumors have reported that alterations in p53 expression and detection of TP53 mutations are associated with clinical aggressiveness and poor response to specific therapies. However, there is no general agreement regarding the optimal technical approach to the analysis of p53. We have studied 100 primary colorectal […]
J. Baselga, M.A. Cañadas, J. Codony, J.A. Hueto, A. Arcas, A. Lladó, X. Puig, M. Guix, G. Raspall, J. Albanell.
The epidermal growth factor receptor (EGFr) is frequently overexpressed in head and neck tumors. Therapeutic strategies directed at preventing or reversing activation of the EGFr are being studied in the clinic. In this setting, assays to determinate the level of EGRr activation prior and during therapy could be instrumental to find the optimal biological dose of anti-receptor therapies. We have studied […]
M. Guix Pericas 1,2, C. Cordón Cardó 1,2,3, M. A. Cañadas Bouzas 1, A. Colomer Valero 2, X. Puig Torrus 1,2.
1HISTOPAT S.A. Laboratoris. 2BIOPAT. Biopatologia molecular S.L. Grup Assistència. Barcelona. 3Memorial Sloan Kettering Cancer Center. Division of Molecular Pathology. Nueva York.
INTRODUCCIÓN
El carcinoma de mama es una de las neoplasias malignas más frecuentes y una de las primeras causas de muerte por cáncer. En la última década se ha incrementado notablemente su detección clínica y radiológica en estadios incipientes, y el […]